We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Breath Test Detects and Diagnoses Stomach Cancer

By LabMedica International staff writers
Posted on 19 Mar 2013
Print article
A simple test that analyzes the chemical signature of a patient's exhaled breath could help diagnose stomach cancer and distinguish it from benign gastric conditions.

The breath test will offer an easier screening tool than endoscopy, where a specially trained medical professional examines the inside of the stomach via a tube inserted down the patient's gullet, and sometimes also retrieves a biopsy sample of the stomach lining.

Scientists at the Technion, the Israel Institute of Technology (Haifa, Israel) used nanomaterial-based sensors to analyze alveolar exhaled breath samples from 130 patients who had undergone endoscopy, and some were biopsied. There were 37 patients who had been diagnosed with stomach cancer, 32 had ulcers, and 61 had less severe stomach complaints. The samples were from patients attending the Anhui Medical University (Hefei, China).

The breath samples were characterized with an array of 14 nanomaterial-based sensors, combined with a statistical pattern recognition algorithm, with the aim of identifying specific patterns, the so-called breath prints for gastric cancer (GC) and nonmalignant gastric conditions, and other subcategories. The sensors included layers of gold nanoparticles with 11 different organic ligands and layers of single-walled carbon nanotubes capped with four different organic overlayers.

The nanomaterial sensors showed an over 90% success rate in distinguishing the patients with stomach cancer from those with more benign complaints. These sensors were more than 90% accurate at distinguishing early from late stage stomach cancers. Chemical analysis found that five volatile organic compounds, 2-propenenitrile, 2-butoxy-ethanol, furfural, 6-methyl-5-hepten-2-one and isoprene were significantly elevated in patients with GC and/or peptic ulcer, as compared with less severe gastric conditions. The encouraging preliminary results from the study have initiated a multicenter clinical trial with considerably increased sample size to confirm the observed breath prints.

The authors suggested that there is a high demand, especially in the developing world, for a simple and noninvasive test for selecting the individuals at increased risk that should undergo the endoscopic examination. Hossam Haick, PhD, a professor at the Technion and senior author of the study said, "The promising findings from this early study suggest that using a breath test to diagnose stomach cancers, as well as more benign complaints, could be a future alternative to endoscopies, which can be costly and time consuming, as well as unpleasant to the patient." The study was published on March 5, 2013, in the British Journal of Cancer.

Related Links:

Technion, the Israel Institute of Technology
Anhui Medical University


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac
New
Immunoassays and Calibrators
QMS Tacrolimus Immunoassays

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.